vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 19.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
ESPR vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $197.3M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 19.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $197.3M | ||
| Q3 25 | $87.3M | $186.7M | ||
| Q2 25 | $82.4M | $214.2M | ||
| Q1 25 | $65.0M | $209.6M | ||
| Q4 24 | $69.1M | $208.5M | ||
| Q3 24 | $51.6M | $174.8M | ||
| Q2 24 | $73.8M | $197.2M | ||
| Q1 24 | $137.7M | $195.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-562.8M | ||
| Q2 25 | $-12.7M | $54.8M | ||
| Q1 25 | $-40.5M | $32.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $24.7M | ||
| Q2 24 | $-61.9M | $40.8M | ||
| Q1 24 | $61.0M | $38.9M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -301.5% | ||
| Q2 25 | -15.4% | 25.6% | ||
| Q1 25 | -62.2% | 15.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 14.1% | ||
| Q2 24 | -83.9% | 20.7% | ||
| Q1 24 | 44.3% | 19.9% |
| Q4 25 | $0.32 | $0.36 | ||
| Q3 25 | $-0.16 | $-4.00 | ||
| Q2 25 | $-0.06 | $0.43 | ||
| Q1 25 | $-0.21 | $0.26 | ||
| Q4 24 | $-0.14 | $0.38 | ||
| Q3 24 | $-0.15 | $0.20 | ||
| Q2 24 | $-0.33 | $0.32 | ||
| Q1 24 | $0.34 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $620.0M |
| Stockholders' EquityBook value | $-302.0M | $3.4B |
| Total Assets | $465.9M | $24.5B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $-302.0M | $3.4B | ||
| Q3 25 | $-451.4M | $3.4B | ||
| Q2 25 | $-433.5M | $3.5B | ||
| Q1 25 | $-426.2M | $3.5B | ||
| Q4 24 | $-388.7M | $3.5B | ||
| Q3 24 | $-370.2M | $3.5B | ||
| Q2 24 | $-344.2M | $3.5B | ||
| Q1 24 | $-294.3M | $3.4B |
| Q4 25 | $465.9M | $24.5B | ||
| Q3 25 | $364.0M | $24.2B | ||
| Q2 25 | $347.1M | $26.7B | ||
| Q1 25 | $324.0M | $26.8B | ||
| Q4 24 | $343.8M | $26.9B | ||
| Q3 24 | $314.1M | $27.3B | ||
| Q2 24 | $352.3M | $27.4B | ||
| Q1 24 | $373.1M | $27.4B |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $449.5M |
| Free Cash FlowOCF − Capex | — | $411.4M |
| FCF MarginFCF / Revenue | — | 208.5% |
| Capex IntensityCapex / Revenue | 0.0% | 19.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $449.5M | ||
| Q3 25 | $-4.3M | $223.4M | ||
| Q2 25 | $-31.4M | $77.6M | ||
| Q1 25 | $-22.6M | $32.8M | ||
| Q4 24 | $-35.0M | $425.9M | ||
| Q3 24 | $-35.3M | $199.4M | ||
| Q2 24 | $-7.2M | $86.1M | ||
| Q1 24 | $53.8M | $57.6M |
| Q4 25 | — | $411.4M | ||
| Q3 25 | — | $216.7M | ||
| Q2 25 | — | $66.3M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $380.4M | ||
| Q3 24 | $-35.5M | $187.7M | ||
| Q2 24 | $-7.3M | $72.7M | ||
| Q1 24 | $53.8M | $47.7M |
| Q4 25 | — | 208.5% | ||
| Q3 25 | — | 116.1% | ||
| Q2 25 | — | 31.0% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 182.5% | ||
| Q3 24 | -68.7% | 107.4% | ||
| Q2 24 | -9.9% | 36.9% | ||
| Q1 24 | 39.0% | 24.5% |
| Q4 25 | 0.0% | 19.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 5.3% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 21.8% | ||
| Q3 24 | 0.3% | 6.7% | ||
| Q2 24 | 0.1% | 6.8% | ||
| Q1 24 | 0.1% | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | 0.88× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SFNC
Segment breakdown not available.
